Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04650321 · ClinicalTrials.gov registry record · Phase 4
Home Based Infusions for Ocrelizumab
A Phase 4 study of Multiple Sclerosis, sponsored by University of Colorado, Denver.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 110
- Enrollment target
- 1
- Study location
NCT04650321 is a Phase 4 study of Multiple Sclerosis that is actively recruiting participants, run by University of Colorado, Denver. The registered enrollment target is 110 participants, below the 585-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (81% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04650321, a Phase 4 study of Multiple Sclerosis, is actively recruiting participants, sponsored by University of Colorado, Denver.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 110 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal is to assess the safety and effectiveness of home ocrelizumab infusion.
Conditions Studied
Interventions
- DRUG Ocrelizumab at home
Study Locations (1)
Colorado
- Amerita - Centennial
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 110 participants |
| Start Date | 2021-03-01 |
| Est. Completion | 2021-08-31 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04650321
The ClinicalTrials.gov registry entry for NCT04650321 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 110 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 585-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (81% lower). The listed sponsor is University of Colorado, Denver, which has 1,283 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Multiple Sclerosis appearing as the primary indexed condition, and to 1 intervention - of which Ocrelizumab at home is the first listed.
NCT04650321 reports 1 study location spanning 1 distinct geographic area - top geographies include Colorado.
Frequently Asked Questions
What is clinical trial NCT04650321 about?
NCT04650321 is a clinical study titled "Home Based Infusions for Ocrelizumab". The goal is to assess the safety and effectiveness of home ocrelizumab infusion.
What is the current status of trial NCT04650321?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 110 participants. The study started on 2021-03-01. Estimated completion is 2021-08-31.
What conditions does trial NCT04650321 study?
This clinical trial studies the following conditions: Multiple Sclerosis.
What interventions are being tested in trial NCT04650321?
The interventions under investigation include: Ocrelizumab at home (DRUG).
Who is sponsoring clinical trial NCT04650321?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04650321 being conducted?
This trial has 1 study location across Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Sclerosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Concentration of Ofatumumab in the Breast Milk of Lactating Women With Relapsing Forms of Multiple Sclerosis
RECRUITING · Phase 4
-
Ublituximab (Briumvi) for Early Forms of Relapsing Multiple Sclerosis
RECRUITING · Phase 4
-
Glucose Consumption in MS Using [F-18]FDG-PET
RECRUITING · Phase 4
-
Ocrelizumab Discontinuation in Relapsing Multiple Sclerosis
RECRUITING · Phase 4
-
Dalfampridine Combined With Physical Therapy for Mobility Impairment in Multiple Sclerosis
RECRUITING · Phase 4
-
Cladribine Tablets After Treatment With Natalizumab (CLADRINA)
ACTIVE NOT RECRUITING · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.